Jade Biosciences, Inc.
NASDAQ:JBIOBiotechnology
-$0.21 today
- Market cap
- $1.07B
- Beta
- 1.45
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$2.24
Volume 0.79M
Average 0.83M
JBIO Total Non-current Liabilities
All obligations due after more than one year.
Jade Biosciences, Inc.NASDAQ: JBIO
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities rises 870.0% from a year ago
Total non-current liabilities stood at $679K at the end of Q1 FY2026, up 870.0% from a year earlier and down 6.2% from the prior quarter. Over 3 fiscal years it compounded at -2.3% a year.
Context
- Total non-current liabilities amounted to 0.2% of total assets at the end of Q1 FY2026, up 0.1 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total non-current liabilities keeps rising in the next quarterly balance sheet after a +870.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 724K USD
- Year-over-year change
- +934.3%
- 4-year CAGR
- +16.4%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 724K | +934.3% |
| FY2024 | 2024-12-31 | 70K | -78.5% |
| FY2023 | 2023-12-31 | 325K | -58.1% |
| FY2022 | 2022-12-31 | 776K | +96.5% |
| FY2021 | 2021-12-31 | 395K | — |
Total Non-current Liabilities vs competitors
How JBIO compares with its peers on the latest reported figures
- JBIO's Mar 2026 total non-current liabilities of $679K is the 8th highest of the 9 companies compared; the peer median is $29.74M.
- Its year-over-year change of +870.0% is the highest of 9, against a peer median of +1.3%.
- Total non-current liabilities amounts to 0.2% of total assets for JBIO, versus a peer median of 13.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $100.24M | +34.2% | +465.8% | 25.0% | |
| Jun 2026 | $76.91M | +0.3% | +38.4% | 14.4% | |
| Mar 2026 | $32.75M | -12.8% | +219.4% | 22.3% | |
| Mar 2026 | $31.77M | +847.5% | +44.6% | 12.4% | |
| Mar 2026 | $27.7M | -14.8% | -6.4% | 13.9% | |
| Mar 2026 | $12.02M | -86.2% | — | 12.6% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $4.65M | +2.3% | +15.7% | 1.8% |
| Mar 2026 | $679K | +870.0% | -2.3% | 0.2% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $0 | +100.0% | — | 0.0% |
| Peer median (excluding JBIO) | $29.74M | +1.3% | +41.5% | 13.3% | |
Competitors are the stored peer set for JBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 54.2M | 22.4M | 23.49M | 33.75M | 88.44M |
| Short-term Investments | 113.18M | 106.82M | 98.95M | 44.87M | 247.72M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 240K | 295K | 250K | 845K | 0 |
| Total Current Assets | 174.33M | 131.5M | 124.23M | 80.12M | 336.16M |
| Property, Plant & Equipment (Net) | 728K | 1.25M | 902K | 215K | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 302K | 2.56M | 2.28M | 0 | 13.62M |
| Total Non-current Assets | 1.03M | 3.8M | 3.19M | 215K | 13.62M |
| Total Assets | 175.36M | 135.3M | 127.42M | 80.33M | 349.78M |
| Account Payables | 1.21M | 2.58M | 2.4M | 224K | 2.15M |
| Short-term Debt | 192K | 385K | 420K | 417K | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 360K | 3.13M | 10.45M | 319K | 3.32M |
| Total Current Liabilities | 2.55M | 7.78M | 17.64M | 3.83M | 16.54M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 13K | 71K | 70K | 70K | 0 |
| Total Non-current Liabilities | 395K | 776K | 325K | 70K | 724K |
| Total Liabilities | 2.95M | 8.56M | 17.96M | 3.9M | 17.26M |
| Common Stock | 2K | 2K | 3K | 3K | 5K |
| Retained Earnings | (36.39M) | (87.9M) | (163.42M) | (233.05M) | (174.39M) |
| Accumulated OCI | (59K) | (466K) | 237K | 105K | 129K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 172.42M | 126.74M | 109.46M | 76.43M | 332.52M |
| Total Debt | 574K | 1.09M | 675K | 417K | 724K |
| Net Debt | (53.62M) | (21.31M) | (22.82M) | (33.33M) | (87.71M) |
Jade Biosciences, Inc.
NASDAQ:JBIO
Intrinsic Alpha fair value
Locked
Current Price
$15.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.